UCB Receives EMEA Positive Opinion and FDA Approvable Letter for Keppra® (levetiracetam) Intravenous Administration
UCB also received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for Keppra® (levetiracetam) Injection 100 mg/mL for use as adjunctive therapy in the treatment of partial onset seizures in adult patients with epilepsy. In the approvable letter, the FDA has requested revised product labelling as well as some additional information regarding manufacturing to finalize its review. UCB has already submitted the requested information to the FDA.
Other news from the department research and development
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.